Implexis Ltd Secures £250k Seed Funding

An estimated £250k seed round has been secured by Implexis Ltd to support its proprietary platform. Based in London, the company aims to accelerate drug formulation development, reduce time-to-market, minimize experimental costs, and discover optimal formulations.

Incorporated in March 2025, the startup also lists the manufacture of pharmaceutical preparations and business and domestic software development among its activities.

The funding allotment occurred in June (with the formal filing completed in July).